The purpose of this study is to find the level of aerobic exercise (AT) that is practical, is safe, and has positive effects on the body that may reduce the side effects of therapy. The study will also look at the way the body responds to exercise and whether there are differences in treatment. This will include looking at the highest treatment dose participants receive, how many people stop, delay, or reduce the treatment, and whether additional medication is needed to treat side effects of therapy.
Aged ≥18 years
Histological confirmation
As per standard of care imaging
Scheduled to receive neoadjuvant chemotherapy or chemotherapy for newly diagnosed metastatic disease
Enrollment onto any other lifestyle interventional investigational study, except interventions determined by the PI not to confound study outcomes
Receiving treatment for any other diagnosis of invasive cancer
Mental impairment leading to inability to cooperate
Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation
Parallel
structured treadmill walking
BehavioralThree doses of AT (i.e., 90, 150, or 300 mins/week) will be tested. All doses will consist of individualized walking delivered up to 7 times per week delivered throughout treatment.
proportion of patients achieving (ratio of delivered to planned treatment) RDI ≥ 90%
RDI (%) will be calculated as the ratio of delivered to planned dose intensity (delivered dose intensity/planned dose intensity).
Click on the lead sponsor to view all of their trials.
